These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

513 related items for PubMed ID: 23664150

  • 1. Subfoveal fibrosis in eyes with neovascular age-related macular degeneration treated with intravitreal ranibizumab.
    Bloch SB, Lund-Andersen H, Sander B, Larsen M.
    Am J Ophthalmol; 2013 Jul; 156(1):116-124.e1. PubMed ID: 23664150
    [Abstract] [Full Text] [Related]

  • 2. Results of intravitreal ranibizumab with a prn regimen in the treatment of extrafoveal and juxtafoveal neovascular membranes in age-related macular degeneration.
    Giacomelli G, Giansanti F, Finocchio L, Biagini I, Bacherini D, Virgili G, Menchini U.
    Retina; 2014 May; 34(5):860-7. PubMed ID: 24756034
    [Abstract] [Full Text] [Related]

  • 3. Subfoveal choroidal thickness after ranibizumab therapy for neovascular age-related macular degeneration: 12-month results.
    Yamazaki T, Koizumi H, Yamagishi T, Kinoshita S.
    Ophthalmology; 2012 Aug; 119(8):1621-7. PubMed ID: 22551738
    [Abstract] [Full Text] [Related]

  • 4. Subfoveal choroidal thickness as a potential predictor of visual outcome and treatment response after intravitreal ranibizumab injections for typical exudative age-related macular degeneration.
    Kang HM, Kwon HJ, Yi JH, Lee CS, Lee SC.
    Am J Ophthalmol; 2014 May; 157(5):1013-21. PubMed ID: 24487050
    [Abstract] [Full Text] [Related]

  • 5. Visual and anatomical outcomes of intravitreal aflibercept in eyes with persistent subfoveal fluid despite previous treatments with ranibizumab in patients with neovascular age-related macular degeneration.
    Kumar N, Marsiglia M, Mrejen S, Fung AT, Slakter J, Sorenson J, Freund KB.
    Retina; 2013 Sep; 33(8):1605-12. PubMed ID: 23549101
    [Abstract] [Full Text] [Related]

  • 6. Implementation studies of ranibizumab for neovascular age-related macular degeneration.
    Bloch SB.
    Acta Ophthalmol; 2013 Nov; 91 Thesis7():1-22. PubMed ID: 24206851
    [Abstract] [Full Text] [Related]

  • 7. Predictive value of spectral-domain optical coherence tomography features in assessment of visual prognosis in eyes with neovascular age-related macular degeneration treated with ranibizumab.
    Mathew R, Richardson M, Sivaprasad S.
    Am J Ophthalmol; 2013 Apr; 155(4):720-6, 726.e1. PubMed ID: 23317653
    [Abstract] [Full Text] [Related]

  • 8. Ranibizumab versus Bevacizumab for Neovascular Age-related Macular Degeneration: Results from the GEFAL Noninferiority Randomized Trial.
    Kodjikian L, Souied EH, Mimoun G, Mauget-Faÿsse M, Behar-Cohen F, Decullier E, Huot L, Aulagner G, GEFAL Study Group.
    Ophthalmology; 2013 Nov; 120(11):2300-9. PubMed ID: 23916488
    [Abstract] [Full Text] [Related]

  • 9. One-year outcomes of less frequent bevacizumab in age-related macular degeneration.
    Sonmez K, Sonmez PA, Ozkan SS, Atmaca LS.
    Retina; 2011 Apr; 31(4):645-53. PubMed ID: 21358363
    [Abstract] [Full Text] [Related]

  • 10. Prognostic factors of eyes with naïve subfoveal myopic choroidal neovascularization after intravitreal bevacizumab.
    Yang HS, Kim JG, Kim JT, Joe SG.
    Am J Ophthalmol; 2013 Dec; 156(6):1201-1210.e2. PubMed ID: 24075429
    [Abstract] [Full Text] [Related]

  • 11. Epimacular brachytherapy for neovascular age-related macular degeneration (CABERNET): fluorescein angiography and optical coherence tomography.
    Jackson TL, Dugel PU, Bebchuk JD, Smith KR, Petrarca R, Slakter JS, Jaffe GJ, Nau JA, CABERNET Study Group.
    Ophthalmology; 2013 Aug; 120(8):1597-603. PubMed ID: 23490325
    [Abstract] [Full Text] [Related]

  • 12. Systemic beta-blockers may reduce the need for repeated intravitreal injections in patients with wet age-related macular degeneration treated by bevacizumab.
    Montero JA, Ruiz-Moreno JM, Sanchis-Merino E, Perez-Martin S.
    Retina; 2013 Mar; 33(3):508-12. PubMed ID: 23099497
    [Abstract] [Full Text] [Related]

  • 13. Effects of ranibizumab in patients with subfoveal choroidal neovascularization attributable to age-related macular degeneration.
    Rothenbuehler SP, Waeber D, Brinkmann CK, Wolf S, Wolf-Schnurrbusch UE.
    Am J Ophthalmol; 2009 May; 147(5):831-7. PubMed ID: 19217019
    [Abstract] [Full Text] [Related]

  • 14. Intravitreal bevacizumab therapy on an as-per-needed basis in subfoveal choroidal neovascularization secondary to pathological myopia: 2-year outcomes of a prospective case series.
    Iacono P, Parodi MB, Papayannis A, Kontadakis S, Sheth S, Bandello F.
    Retina; 2011 Oct; 31(9):1841-7. PubMed ID: 21775926
    [Abstract] [Full Text] [Related]

  • 15. Intravitreal bevacizumab for exudative age-related macular degeneration: effect on different subfoveal membranes.
    Tao Y, Jonas JB.
    Retina; 2010 Oct; 30(9):1426-31. PubMed ID: 20539255
    [Abstract] [Full Text] [Related]

  • 16. REFRACTORY INTRARETINAL OR SUBRETINAL FLUID IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION TREATED WITH INTRAVITREAL RANIZUBIMAB: Functional and Structural Outcome.
    Gianniou C, Dirani A, Jang L, Mantel I.
    Retina; 2015 Jun; 35(6):1195-201. PubMed ID: 25650710
    [Abstract] [Full Text] [Related]

  • 17. Intravitreal ranibizumab for the treatment of inflammatory choroidal neovascularization.
    Rouvas A, Petrou P, Douvali M, Ntouraki A, Vergados I, Georgalas I, Markomichelakis N.
    Retina; 2011 May; 31(5):871-9. PubMed ID: 21358461
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Treat-and-extend bevacizumab for neovascular age-related macular degeneration: the importance of baseline characteristics.
    Rush RB, Simunovic MP, Vandiver L, Aragon AV, Ysasaga JE.
    Retina; 2014 May; 34(5):846-52. PubMed ID: 24240560
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.